Esperovax

Esperovax has developed a proprietary method for bioengineering probiotic yeast to continuously deliver high concentrations of vaccine antigens in the gut, leveraging the innovative capability of targeted oral mRNA vaccines to combat some of the world’s most devastating diseases. These antigens are directly delivered to the lymphoid tissues of the intestinal mucosa in the form of enveloped virus-like particles (eVLPs), eliciting robust immune protection.